According to the National Institutes of Health’s Center National Center for Advancing Translational Sciences, many drugs approved for other uses already have been tested in humans, so detailed information is available on their pharmacology, formulation, and potential toxicity.
Therefore, trying a Food and Drug Administration (FDA)-approved drug for one disease as a new therapy for an unrelated disease could allow the treatment to be ready for clinical trials more quickly thus speeding the FDA’s review and, if approved, its integration into health care.1 This is more commonly referred to as “drug re-purposing” or “off-label use.”
FDA approval on a repurposed drug can take approximately three to four years as compared to an investigational new drug (IND), which may take greater than 10 years. The approval rate for a repurposed drug in approximately 30 percent1 whereas an IND is less than 12 percent.2
In an effort to combat the coronavirus (COVID-19), front-line physicians have already repurposed two drugs: hydroxychloroquine (brand name Plaquenil®—commonly used for malaria and rheumatoid arthritis) and azithromycin (multiple brand names including Zithromax® Zithromax Tri-Pak®, Azythromycin Dose Pack®, Zithromax Z-Pak® and Zmax®)—a macrolide antibiotic used to treat common infections of the respiratory system, the ear and the eye.
Both drugs are known to be low-risk ototoxic agents; however, there is no published research about the synergistic ototoxic effects of these drugs in treating COVID-19. At the present time, it is not known if hearing loss and/or tinnitus will be a late onset of this COVID-19 drug intervention. Therefore, case history questions will need to be added to accommodate this new population of patients.
Related Posts
Communication Sciences and Disorders Graduate Admissions Data
Watts and colleagues (2023) examined the relationship between sociodemographic factors and academic factors on an offer of admission to a graduate program in Communication Sciences and Disorders (CSD). Sociodemographic factors included age, disadvantaged socioeconomic status, race/ethnicity, first-generation status, and the ability to speak more than one language at an advanced level. Academic factors included the…
Hearing Loss and Dementia in Older Adults
The relationship between hearing and cognition is a highly discussed and researched topic in the field of audiology. In a recent article in Canadian Audiologist (2023), Kathy Pichora-Fuller, PhD, reviews what we do and do not know about hearing and cognition as well as expected advances in research in 2023. She reminds readers that an…
Classification of Persistent Postural Perceptual Dizziness and Complex Cases
A recent study suggests that patients are more likely to develop persistent postural perceptual dizziness (PPPD) if they have a history of multiple episodic conditions such as benign paroxysmal positional vertigo (BPPV), vestibular migraine (VM), or Meniere’s disease (MD) compared to those with a history of a single episodic condition. PPPD is a relatively new…